Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro

Kidney International

Volumn 61, Issue 4, 2002, Pages 1365-1376

  Routh, Robert Earl ^a,b   Johnson, John Hardwick ^a,b   McCarthy, Kevin John ^a,b  

^a School of Medicine   (United States)

^b PFIZER INC   (United States)

Author keywords

Connective tissue matrix; Diabetes; Fibrosis; Glomerulosclerosis; Hyperglycemia; Progressive renal disease

Indexed keywords

CLOFIBRATE; COLLAGEN TYPE 1; GLUCOSE; LAMININ; MANNITOL; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TROGLITAZONE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONNECTIVE TISSUE; CONTROLLED STUDY; CULTURE MEDIUM; DIABETES MELLITUS; DRUG RESPONSE; FIBROSIS; GLOMERULOSCLEROSIS; HYPERGLYCEMIA; IN VITRO STUDY; MESANGIUM CELL; MORPHOLOGICAL TRAIT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; PROTEIN SYNTHESIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 0036230990     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00277.x     Document Type: Article

References (57)

1. Baseline analysis of renal function in the diabetes control and complications trial
2. Sulfonylureas
3. Peroxisome proliferator-receptor γ and metabolic disease
4. Peroxisome proliferator-activated receptor gamma (PPARgamma) activation and its consequences in humans
5. Peroxisome proliferator-activated receptors in the cardiovascular system
6. Control of the peroxisomal oxidation pathway by a novel family of nuclear hormone receptors
7. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors
8. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene
9. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression
10. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation
11. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors
12. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation
13. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma
14. Bezafibrate reduces blood glucose in type 2 diabetes mellitus
15. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
16. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation
17. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat
18. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion
19. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats
20. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients
21. Isolation of glomeruli from mammalian kidneys by graded sieving
22. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats
23. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against non-diabetic glomerulosclerosis in rats
24. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system
25. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
26. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: No alteration in adipose tissue of obese and NIDDM patients
27. The organization, promoter analysis, and expression of the human PPARgamma gene
28. Expression of peroxi-some proliferator-activated receptors in urinary tract of rabbits and humans
29. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney
30. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
31. Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation
32. Advanced glycation end product-induced peroxisome proliferator-activated receptor gamma gene expression in the cultured mesangial cells
33. Lessons from kidney biopsies
34. Structure-function relationships in diabetic nephropathy: Lessons and limitations
35. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator
36. Mediators of hyperglycemia and the pathogenesis of matrix accumulation in diabetic renal disease
37. Structure-function relationships associated with extracel-lular matrix alterations in diabetic glomerulopathy
38. Pathogenesis of non-immune glomerulosclerosis: Studies in animals and potential applications to humans
39. Heparan sulfate proteoglycan in the glomerular basement membrane in type I diabetes mellitus
40. 35S]-labeled glomerular basement membrane
41. Undersulfation of glomerular basement membrane heparan sulfate in experimental diabetes and lack of correction with aldose reductase inhibition
42. Decreased de novo synthesis of glomerular proteoglycans in diabetes: Biochemical and autoradiographic evidence
43. Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy
44. Regulation of renal laminin in mice with type II diabetes
45. Cell-matrix interactions in the glomerular mesangium
46. Development of the glomerular basement membrane and mesangial matrix: Asynchronous maturation of glomerular extracellular matrices
47. Glomerular remodelling after inflammatory injury
48. The glomerular response to injury: Progression or resolution?
49. Mesangial deposition of type I collagen in human glomerulosclerosis
50. Collagen polymorphism in cultured rat kidney mesangial cells
51. Extracellular matrix phenotype of rat mesangial cells in culture. Biosynthesis of collagen types I, III, IV, and V and a low molecular weight collagenous component and their regulation by dexamethasone
52. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β
53. Peroxisome proliferator-activated receptors and hepatic stellate cell activation
54. Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor-alpha exert synergistic antiproliferative effects on human coronary artery smooth muscle cells
55. Expression and function of PPAR-gamma in rat and human vascular smooth muscle cells
56. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
57. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells